Bank of America Corp DE Buys 367,720 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Bank of America Corp DE increased its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 160.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 597,319 shares of the company's stock after acquiring an additional 367,720 shares during the quarter. Bank of America Corp DE owned about 0.47% of Humacyte worth $3,016,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after acquiring an additional 543,995 shares during the last quarter. Geode Capital Management LLC grew its holdings in Humacyte by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock valued at $10,785,000 after buying an additional 94,915 shares in the last quarter. CenterBook Partners LP acquired a new position in Humacyte in the 4th quarter valued at $6,463,000. Northern Trust Corp grew its holdings in Humacyte by 11.5% in the 4th quarter. Northern Trust Corp now owns 901,194 shares of the company's stock valued at $4,551,000 after buying an additional 92,708 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Humacyte by 7.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 775,718 shares of the company's stock valued at $3,917,000 after buying an additional 54,400 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Humacyte

In related news, Director Kathleen Sebelius acquired 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Dale A. Sander acquired 20,000 shares of the stock in a transaction dated Thursday, April 10th. The shares were bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. The trade was a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by insiders.

Humacyte Price Performance

Shares of HUMA stock traded down $0.05 on Monday, hitting $2.62. 4,518,230 shares of the company's stock were exchanged, compared to its average volume of 3,782,446. The stock has a market cap of $406.41 million, a P/E ratio of -1.96 and a beta of 1.64. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $9.79. The company has a 50 day moving average of $1.71 and a 200 day moving average of $3.27.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. Sell-side analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on HUMA shares. Benchmark decreased their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, May 13th. Finally, HC Wainwright assumed coverage on Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.